Parexel

Antibody-drug conjugates (ADCs) are transforming cancer treatment by delivering targeted therapies with greater precision and fewer off-target effects than traditional chemotherapy. With nearly 100 ADCs currently in clinical development, the potential is enormous - but so are the complexities of regulatory approval, CMC challenges and clinical optimization. In this edition of the New Medicines, Novel Insights newsletter, Parexel experts and former regulators explore the evolving landscape of ADC development. From regulatory strategies to clinical best practices, we discuss how a thoughtful, multi-perspective approach can help bring these groundbreaking treatments to patients faster. Read the full article to learn more about the challenges and opportunities in ADC development. #ADC #Oncology #DrugDevelopment #NovelInsights

Parexel CEO Peyton Howell is in the hot seat for the new season of NYSE's The Cure(ious)! 🎬 Follow along as top leaders and thinkers in the life sciences industry share career insights, personal wisdom and their visions for the future of healthcare. Three questions. Three bowls. One mission: to inspire and spark curiosity in health innovation. Find out what makes them curious: https://lnkd.in/eRMjFJnX 📽 credit to NYSE #TheCurious #NYSE

Innovations that accelerate clinical trials are now commonplace in oncology and other therapeutic areas, yet neuroscience trials remain primarily traditional due to disease heterogeneity and the absence of actionable biomarkers. In this article from our latest report, Parexel experts Andreas Lysandropoulos MD, PhD, Simona Stankeviciute and Amy Pace review recent advances in the clinical research field that suggest the time has come for invention and cross-fertilization that promise to accelerate neuroscience drug development. Learn more here: 🔗 https://lnkd.in/eGPcRFjd #Neuroscience #Neurology #Innovation #NovelInsights

This month, our Black Employees Advisory Consortium (BEACON) came together to honor and celebrate U.S. Black History Month. 📷   BEACON, now 260+ members strong, has been driving positive change over the past four years by: ✔ Fostering inclusion within Parexel ✔ Promoting patient access and representation in clinical research ✔ Supporting Black Women In Clinical Research ® events ✔ Engaging in local community service This month, BEACON also hosted a virtual book club discussion on "The Pact: Three Young Men Make a Promise and Fulfill a Dream," as well as an educational Lunch & Learn for colleagues on how to drive meaningful change in how medicine is taught and practiced. #BlackHistoryMonth #ClinicalResearch #ProudToBeParexel

We're only beginning to see the full potential of AI in clinical research. From optimizing clinical trial design, simplifying complex tasks and accelerating timelines, AI is transforming the way we work – helping us move faster, think bigger and collaborate more effectively.   This week, we spoke with Jacqueline Vanderpuye-Orgle, Vice President and Global Head of Advanced Analytics at Parexel, about the multifaceted role AI plays in trials and evidence generation today – and what the future holds.   Click through to see Jackie's insights on how AI is shaping the industry and accelerating the path to better patient outcomes.   #AIandMe #ArtificialIntelligence #ClinicalResearch #HEOR #RWE

Looking for a role in clinical operations? Nirmallya started as a Senior Clinical Research Associate (CRA) during a critical phase of Parexel's India operations. As Parexel established its clinical research presence in India, Nirmallya's role evolved. He progressed to leading a team of Clinical Operations Leaders, fostering a culture of trust and empowerment along the way. Learn more about his career path and the opportunities for growth in clinical operations: https://brnw.ch/21wQSAb #ParexelCareers #ClinicalOperations

Meet Parexel's Michelle Major, who leads hiking groups, volunteers in canoe sprinting and aims to officiate at the 2032 Brisbane Olympics! Her life took an unexpected turn in 2021 when mysterious symptoms emerged which led to a diagnosis of an undefined autoimmune disease. ⬇ Read her story and share this post to help us amplify patient voices like Michelle's. Q: Can you describe your rare disease journey? Late in 2021, I developed severe fatigue, an unusual rash, gastrointestinal symptoms and constant joint pain. It was big change of function from competing in a Half Ironman triathlon earlier that year. I was not used to being unwell and was not a very "patient" patient. After 18 months of various medications, I was referred to an immunology tertiary hospital. While they could not diagnose with precision, they prescribed a medication frequently used in immune-related conditions. So far, so good. Q: Why is self-advocacy important? Particularly when working through so many variable and bizarre symptoms, monitoring your own health is key. Each specialist is looking at a different aspect of your health, so you must share the whole you and know your body the best. When asked about advice for others seeking an official diagnosis, Michelle said: 🔹 Perseverance is key as you are moved from specialist to specialist 🔹 Keep track of your symptoms and the impact of medication to report as accurately as possible 🔹 Celebrate short-term success and appreciate that whilst you won't always have a clear path of progress, you can embrace the now. #RareDiseaseDay

We are proud nominees in the upcoming Vaccine Industry Excellence (ViE) Awards for "Best Clinical Trial Network" and "Best Contract Research Organization." Please consider casting your vote for Parexel before Feb. 24! 🔗https://brnw.ch/21wQQ5w #ViEAwards

Last week Parexel announced recipients of our 2024 awards designed to recognize exemplary leadership and outstanding contributions to the organization, our customers and the patients we serve.   Our With Heart™ Awards recognize colleagues who embody our core values and deliver exceptional results:   🌟 Shaun Martin, Ph.D., Vice President, Commercial Strategy 🌟 Bianca Tseng, Executive Director, Project Leadership 🌟 Jeffrey Kopicko, Vice President, Data Operations 🌟 Marty Mahoney, Chief Compliance Officer & Deputy General Counsel   We also were pleased to introduce a new award — the Todd Shuster Award for Leadership in Thought and Conduct —honoring the memory and legacy of Parexel’s Global Head of Hematology/Oncology Todd Shuster, who passed away from cancer in 2022. The award recognizes the Parexel colleague who best demonstrates the leadership values exemplified by Todd: learning, excellence, respect, resolve and ingenuity. The inaugural recipient of this special award is:   🌟 Heidi Cho, Senior Medical Director   The inspiring leaders recognized as part of our 2024 awards demonstrate what it means to work #WithHeart at Parexel. Their dedication and passion make a difference for our teams, our customers and ultimately, for patients worldwide.   Please join us in the comments in congratulating the winners! 👏 #ParexelWithHeart

Digital biomarkers (DBx) are transforming the way we track disease progression in neurological disorders. By using wearables and sensors, they offer continuous, objective data, reducing costs and improving trial efficiency. In the latest New Medicines, Novel Insights newsletter, we explore the opportunities and challenges of DBx in clinical trials for neurodegenerative diseases like Parkinson's and Alzheimer's. With early detection and more precise monitoring, DBx can revolutionize patient care and speed up drug development. Our team at Parexel and Health Advances shares strategies for implementing DBx, from maximizing value in trials to choosing the right technology partners and navigating commercial realities. Discover how investing in digital biomarkers today can lead to more efficient studies and better patient outcomes. #DigitalBiomarkers #Neuroscience #ClinicalTrials #NovelInsights #Neurology